Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)
This trial is active, not recruiting.
|Conditions||ankylosing spondylitis, spinal fractures|
|Start date||January 2005|
|End date||December 2015|
|Trial size||9858 participants|
|Trial identifier||NCT02840695, bDMARD AS Spinal Fractures|
Ankylosing spondylitis (AS) is a rheumatoid disease affecting all segments of the axial skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. During the last decade biological disease modifying anti-rheumatic drugs (bDMARD) have been successfully introduced to reduce the disease activity. It is unclear whether bDMARD treatment had an effect on spinal fracture risk related to AS. This national registry study will investigate the effect of bDMARD treatment on spinal fracture risk in a national cohort of patients with AS.
time frame: 10 years
Male or female participants from 30 years up to 60 years old.
Inclusion Criteria: - age 30-60 years - registered diagnosis of ankylosing spondylitis Exclusion Criteria: - age <30 or >60 years
|Official title||Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)|
Call for more information